EGFL7 Antikörper (AA 30-80) (FITC)
Kurzübersicht für EGFL7 Antikörper (AA 30-80) (FITC) (ABIN733995)
Target
Alle EGFL7 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 30-80
-
Verwendungszweck
- EGFL7 Polyclonal Antibody, FITC Conjugated
-
Homologie
- Human,Mouse,Rat
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from mouse EGFL7
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IF(1:100-500)
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- EGFL7 (EGF-Like-Domain, Multiple 7 (EGFL7))
-
Andere Bezeichnung
- Egfl7
-
Hintergrund
-
Synonyms: Zneu1, VE-statin, Epidermal growth factor-like protein 7, EGF-like protein 7, Multiple epidermal growth factor-like domains protein 7, Multiple EGF-like domains protein 7, NOTCH4-like protein, Vascular endothelial statin, Egfl7, Megf7
Background: Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.
-
Gen-ID
- 353156
-
UniProt
- Q9QXT5
Target
-